Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology
Published in: Clinical and Experimental Nephrology 3/2015

01-06-2015 | Original Article

Hypoadiponectinemia correlates with arterial stiffness in kidney transplantation patients

Authors: Guan-Jin Ho, Ming-Che Lee, Chung-Jen Lee, Yen-Cheng Chen, Bang-Gee Hsu

Published in: Clinical and Experimental Nephrology | Issue 3/2015

Login to get access

Abstract

Background

Adiponectin is a fat-derived hormone produced and secreted exclusively by adipocytes that have anti-atherosclerotic effects. The aim of this study was to evaluate the relationship between fasting serum adiponectin levels and arterial stiffness among kidney transplant (KT) patients.

Methods

Fasting blood samples were obtained from 69 KT patients. Brachial–ankle pulse wave velocity (baPWV) was measured in the right or left brachial artery to the ankle segments using an automatic pulse wave analyzer. Plasma adiponectin levels were measured using a commercial enzyme-linked immunosorbent assay kit. Left or right baPWV values of >14.0 m/s were used to define the high arterial stiffness group.

Results

Thirty-five KT patients (35/69; 50.7 %) were defined in high arterial stiffness group. Diabetes (P = 0.013), smoking (P = 0.001), KT duration (P < 0.001), body weight (P = 0.013), waist circumference (P = 0.013), body mass index (P = 0.001), fasting glucose (P = 0.013), systolic blood pressure (P < 0.001), diastolic blood pressure (P = 0.008), and pulse pressure (P = 0.003) were higher, while serum adiponectin level (P = 0.004) was lower in high arterial stiffness group compared with low arterial stiffness group. Multivariate logistic regression analysis showed that adiponectin (odds ratio 0.90, 95 % confidence interval 0.81–0.99, P = 0.034) was still the independent predictors of arterial stiffness among the KT patients.

Conclusion

Serum fasting adiponectin level was inversely associated with arterial stiffness among KT patients.
Literature
1.
Cavalcante JL, Lima JA, Redheuil A, et al. Aortic stiffness: current understanding and future directions. J Am Coll Cardiol. 2011;57:1511–22.PubMedCrossRef
2.
Liefeldt L, Budde K. Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk. Transpl Int. 2010;23:1191–204.PubMedCrossRef
3.
Khoshdel AR, Carney SL. Arterial stiffness in kidney transplant recipients: an overview of methodology and applications. Urol J. 2008;5:3–14.PubMed
4.
Verbeke F, Maréchal C, Van Laecke S, et al. Aortic stiffness and central wave reflections predict outcome in renal transplant recipients. Hypertension. 2011;58:833–8.PubMedCrossRef
5.
Tomiyama H, Yamashina A. Non-invasive vascular function tests: their pathophysiological background and clinical application. Circ J. 2010;74:24–33.PubMedCrossRef
6.
Tanaka H, Munakata M, Kawano Y, et al. Comparison between carotid–femoral and brachial–ankle pulse wave velocity as measures of arterial stiffness. J Hypertens. 2009;27:2022–7.PubMedCrossRef
7.
Vlachopoulos C, Aznaouridis K, Terentes-Printzios D, et al. Prediction of cardiovascular events and all-cause mortality with brachial–ankle elasticity index: a systematic review and meta-analysis. Hypertension. 2012;60:556–62.PubMedCrossRef
8.
Trujillo ME, Scherer PE. Adipose tissue-derived factors: impact on health and disease. Endocr Rev. 2006;27:762–78.PubMedCrossRef
9.
Windham BG, Griswold ME, Farasat SM, et al. Influence of leptin, adiponectin, and resistin on the association between abdominal adiposity and arterial stiffness. Am J Hypertens. 2010;23:501–7.PubMedCrossRef
10.
Sung SH, Chuang SY, Sheu WH, et al. Relation of adiponectin and high-sensitivity C-reactive protein to pulse-wave velocity and N-terminal pro-B-type natriuretic peptide in the general population. Am J Cardiol. 2009;103:1411–6.PubMedCrossRef
11.
Kawamoto R, Tabara Y, Kohara K, et al. Serum high molecular weight adiponectin correlates with arterial stiffness in community-dwelling persons. Endocr Res. 2011;36:53–63.PubMedCrossRef
12.
Youn JC, Kim C, Park S, et al. Adiponectin and progression of arterial stiffness in hypertensive patients. Int J Cardiol. 2013;163:316–9.PubMedCrossRef
13.
Lee MC, Lee CJ, Ho GJ, et al. Hyperleptinemia positively correlated with metabolic syndrome in renal transplant recipients. Clin Transplant. 2010;24:E124–9.PubMedCrossRef
14.
Lee MC, Lee CJ, Ho GJ, et al. Fasting adiponectin correlates inversely with metabolic syndrome in kidney transplantation patients. Transplant Proc. 2011;43:2601–5.PubMedCrossRef
15.
Hsu BG, Ho GJ, Lee CJ, et al. Inverse association of serum long-acting natriuretic peptide and bone mass density in renal transplant recipients. Clin Transplant. 2012;26:E105–10.PubMedCrossRef
16.
Kubozono T, Miyata M, Ueyama K, et al. Acute and chronic effects of smoking on arterial stiffness. Circ J. 2011;75:698–702.PubMedCrossRef
17.
Kato A, Ishida J, Endo Y, et al. Association of abdominal visceral adiposity and thigh sarcopenia with changes of arteriosclerosis in haemodialysis patients. Nephrol Dial Transplant. 2011;26:1967–76.PubMedCrossRef
18.
Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation. 2006;82:603–11.PubMedCrossRef
19.
Svensson M, Jardine A, Fellström B, et al. Prevention of cardiovascular disease after renal transplantation. Curr Opin Organ Transplant. 2012;17:393–400.PubMed
20.
Strózecki P, Adamowicz A, Włodarczyk Z, et al. Factors associated with increased arterial stiffness in renal transplant recipients. Med Sci Monit. 2010;16:CR301–6.PubMed
21.
22.
Strozecki P, Adamowicz A, Kozlowski M, et al. Progressive arterial stiffening in kidney transplant recipients. Ann Transplant. 2011;16:30–5.PubMed
23.
Stehouwer CD, Henry RM, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia. 2008;51:527–39.PubMedCrossRef
24.
Briet M, Boutouyrie P, Laurent S, et al. Arterial stiffness and pulse pressure in CKD and ESRD. Kidney Int. 2012;82:388–400.PubMedCrossRef
25.
Opazo Saez A, Kos M, Witzke O, et al. Effect of new-onset diabetes mellitus on arterial stiffness in renal transplantation. Transpl Int. 2008;21:930–5.PubMedCrossRef
26.
Sutton-Tyrrell K, Newman A, Simonsick EM, et al. Aortic stiffness is associated with visceral adiposity in older adults enrolled in the study of health, aging, and body composition. Hypertension. 2001;38:429–33.PubMedCrossRef
27.
Hirai T, Okuno A, Souda T, et al. Evaluation of arterial stiffness after successful renal transplantation using brachial–ankle pulse wave velocity. Transplant Proc. 2010;42:4061–3.PubMedCrossRef
28.
Lee M, Choh AC, Demerath EW, et al. Associations between trunk, leg and total body adiposity with arterial stiffness. Am J Hypertens. 2012;25:1131–7.PubMedCentralPubMedCrossRef
29.
Xu A, Vanhoutte PM. Adiponectin and adipocyte fatty acid binding protein in the pathogenesis of cardiovascular disease. Am J Physiol Heart Circ Physiol. 2012;302:H1231–40.PubMedCrossRef
30.
Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol. 2010;314:1–16.PubMedCrossRef
31.
Ikonomidis I, Kadoglou N, Tsiotra PC, et al. Arterial stiffness is associated with increased monocyte expression of adiponectin receptor mRNA and protein in patients with coronary artery disease. Am J Hypertens. 2012;25:746–55.PubMedCrossRef
32.
de Faria AP, Demacq C, Figueiredo VN, et al. Hypoadiponectinemia and aldosterone excess are associated with lack of blood pressure control in subjects with resistant hypertension. Hypertens Res. 2013;36:1067–72.PubMedCrossRef
33.
El Khoudary SR, Barinas-Mitchell E, White J, et al. Adiponectin, systolic blood pressure, and alcohol consumption are associated with more aortic stiffness progression among apparently healthy men. Atherosclerosis. 2012;225:475–80.PubMedCentralPubMedCrossRef
34.
Kato K, Matsuhisa M, Ichimaru N, et al. The impact of new-onset diabetes on arterial stiffness after renal transplantation. Endocr J. 2008;55:677–83.PubMedCrossRef
35.
Joannidès R, Monteil C, de Ligny BH, et al. Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine. Am J Transplant. 2011;11:2414–22.PubMedCrossRef
36.
Gungor O, Kircelli F, Carrero JJ, et al. The effect of immunosuppressive treatment on arterial stiffness and matrix Gla protein levels in renal transplant recipients. Clin Nephrol. 2011;75:491–6.PubMedCrossRef
37.
Shahin Y, Khan JA, Chetter I. Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomised controlled trials. Atherosclerosis. 2012;221:18–33.PubMedCrossRef
38.
Vyssoulis GP, Karpanou EA, Kyvelou SM, et al. Beneficial effect of angiotensin II type 1 receptor blocker antihypertensive treatment on arterial stiffness: the role of smoking. J Clin Hypertens. 2008;10:201–7.CrossRef
39.
Koumaras C, Tziomalos K, Stavrinou E, et al. Effects of renin–angiotensin–aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. J Am Soc Hypertens. 2014;8:74–82.PubMedCrossRef
40.
Becker B, Kronenberg F, Kielstein JT, et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol. 2005;16:1091–8.PubMedCrossRef
41.
Iwashima Y, Horio T, Kumada M, et al. Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol. 2006;98:1603–8.PubMedCrossRef
42.
Nishimura M, Hashimoto T, Kobayashi H, et al. Association of the circulating adiponectin concentration with coronary in-stent restenosis in haemodialysis patients. Nephrol Dial Transplant. 2006;21:1640–7.PubMedCrossRef
43.
Abdallah E, Waked E, Nabil M, et al. Adiponectin and cardiovascular outcomes among hemodialysis patients. Kidney Blood Press Res. 2012;35:247–53.PubMedCrossRef
44.
Roos M, Baumann M, Liu D, et al. Low pre-transplant adiponectin multimers are associated with adverse allograft outcomes in kidney transplant recipients a 3-year prospective study. Regul Pept. 2012;178:11–5.PubMedCrossRef
45.
Cañas L, Bayés B, Granada ML, et al. Is adiponectin a marker of preclinical atherosclerosis in kidney transplantation? Clin Transplant. 2012;26:259–66.PubMedCrossRef
46.
Menon V, Li L, Wang X, et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol. 2006;17:2599–606.PubMedCrossRef
47.
Ohashi N, Kato A, Misaki T, et al. Association of serum adiponectin levels with all-cause mortality in hemodialysis patients. Intern Med. 2008;47:485–91.PubMedCrossRef
48.
49.
Sattar N, Wannamethee G, Sarwar N, et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation. 2006;114:623–9.PubMedCrossRef
50.
Hao G, Li W, Guo R, et al. Serum total adiponectin level and the risk of cardiovascular disease in general population: a meta-analysis of 17 prospective studies. Atherosclerosis. 2013;228:29–35.PubMedCrossRef
51.
Kanhai DA, Kranendonk ME, Uiterwaal CS, et al. Adiponectin and incident coronary heart disease and stroke. A systematic review and meta-analysis of prospective studies. Obes Rev. 2013;14:555–67.PubMedCrossRef
52.
SookLee E, Park SS, Kim E, et al. Association between adiponectin levels and coronary heart disease and mortality: a systematic review and meta-analysis. Int J Epodemiol. 2013;42:1029–39.CrossRef
53.
Wu Z, Cheng Y, Aung LH, et al. Association between adiponectin concentrations and cardiovascular disease in diabetic patients: a systematic review and meta-analysis. PLoS ONE. 2013;8:e78485.PubMedCentralPubMedCrossRef
54.
Wu ZJ, Cheng YJ, Gu WJ, et al. Adiponectin is associated with increased mortality in patients with already established cardiovascular disease: a systematic review and meta-analysis. Metabolism. 2014 (in press).
55.
Nanayakkara PW, Le Poole CY, Fouque D, et al. Plasma adiponectin concentration has an inverse and a non linear association with estimated glomerular filtration rate in patients with K/DOQI 3–5 chronic kidney disease. Clin Nephrol. 2009;72:21–30.PubMedCrossRef
56.
Zoccali C, Mallamaci F, Tripepi G, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol. 2002;13:134–41.PubMedCrossRef
Metadata
Title
Hypoadiponectinemia correlates with arterial stiffness in kidney transplantation patients
Authors
Guan-Jin Ho
Ming-Che Lee
Chung-Jen Lee
Yen-Cheng Chen
Bang-Gee Hsu
Publication date
01-06-2015
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 3/2015
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-014-1010-1

Other articles of this Issue 3/2015

Clinical and Experimental Nephrology 3/2015 Go to the issue

Original Article

Glomerular basement membrane injuries in IgA nephropathy evaluated by double immunostaining for α5(IV) and α2(IV) chains of type IV collagen and low-vacuum scanning electron microscopy

Original Article

Correction of hyponatremia and osmotic demyelinating syndrome: have we neglected to think intracellularly?

Original Article

Nicorandil suppresses urinary protein excretion and activates eNOS in Dahl salt-sensitive hypertensive rats

Original Article

Comparison of predictive value for first cardiovascular event between Japanese GFR equation and coefficient-modified CKD-EPI equation

Original Article

The influences of larger physical constitutions including obesity on the amount of urine protein excretion in primary glomerulonephritis: research of the Japan Renal Biopsy Registry

Original Article

Serum galectin-3 levels were associated with proteinuria in patients with Familial Mediterranean Fever
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits